Tracking the progress of HIV: The impact of point-of-care tests on antiretroviral therapy

Clinical Epidemiology

Volumn 5, Issue 1, 2013, Pages 387-396

  Reid, Steven D ^a   Fidler, Sarah J ^a   Cooke, Graham S ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; BLOOD CELL COUNT; CD4 LYMPHOCYTE COUNT; COMMUNITY LIVING; COUNSELING; DEVELOPING COUNTRY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DRUG EFFICACY; EARLY DIAGNOSIS; EPIDEMIC; GLOMERULUS FILTRATION RATE; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV RAPID TEST; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; KAPOSI SARCOMA; KIDNEY FUNCTION TEST; LABORATORY TEST; LIFE EXPECTANCY; LIVER FUNCTION TEST; MORBIDITY; MORTALITY; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT ATTITUDE; PATIENT CARE; PATIENT MONITORING; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PROCESS DEVELOPMENT; REVIEW; RISK REDUCTION; SCREENING TEST; SEXUAL HEALTH; SEXUALITY; SURVIVAL PREDICTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTICAL TRANSMISSION; VIRUS CHARACTERIZATION; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 84885063197     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S37069     Document Type: Review

References (72)

1. HIV/AIDS: data and statistics [webpage on the Internet]. Geneva: World Health Organization; 2013. Available from: http://www.who.int/hiv/ data/en/index.html. Accessed April 26, 2013.
2. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T- lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):868-871.
3. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984;224(4648):500-503.
4. Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo RC. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science. 1984;224(4648):506-508.
5. Petricciani JC. Licensed tests for antibody to human T-lymphotropic virus type III. Sensitivity and specifcity. Ann Intern Med. 1985;103(5): 726-729.
6. Schorr JB, Berkowitz A, Cumming PD, Katz AJ, Sandler SG. Prevalence of HTLV-III antibody in American blood donors. N Engl J Med. 1985;313(6):384-385.
7. Biggar RJ. The AIDS problem in Africa. Lancet. 1986;1 (8472): 79-83.
8. Downing RG, Otten RA, Marum E, et al. Optimizing the delivery of HIV counseling and testing services: the Uganda experience using rapid HIV antibody test algorithms. J Acquir Immune Defc Syndr Hum Retrovirol. 1998;18(4):384-388.
9. Pai N P, Tulsky J P, Cohan D, Colford JM Jr, Reingold AL. Rapid point-of-care HIV testing in pregnant women: a systematic review and meta-analysis. Trop Med Int Health. 2007;12(2):162-173.
10. HIV Assays: Operational Characteristics (Phase 1). Report 14: Simple/ Rapid Tests. Geneva: World Health Organization; 2004.
11. Cohen R, Lynch S, Bygrave H, et al. Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc. 2009;12:23.
12. Bemelmans M, van den Akker T, Ford N, et al. Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health. 2010; 15(12):1413-1420.
13. Chetty V, Moodley D, Chuturgoon A. Evaluation of a 4th generation rapid HIV test for earlier and reliable detection of HIV infection in pregnancy. J Clin Virol. 2012;54(2):180-184.
14. Wessman MJ, Theilgaard Z, Katzenstein TL. Determination of HIV status of infants born to HIV-infected mothers: a review of the diagnostic methods with special focus on the applicability of p24 antigen testing in developing countries. Scand J Infect Dis. 2012;44(3):209-215.
15. Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med. 2011;9:59.
16. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Geneva: World Health Organization; 2010.
17. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201.
18. Gallant JE, DeJesus E, Arribas JR, et al; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260.
19. Clotet B, Bellos N, Molina JM, et al; POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007; 369(9568):1169-1178.
20. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F; ATHENA national observational cohort study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24(10):1527-1535.
21. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966-971.
22. Datta P, Embree JE, Kreiss JK, et al. Mother-to-child transmission of human immunodeficiency virus type 1: report from the Nairobi Study. J Infect Dis. 1994;170(5):1134-1140.
23. [No authors listed]. Mother-to-child transmission of HIV infection. The European Collaborative Study. Lancet. 1988;2(8619):1039-1043.
24. Stringer JS, Rouse DJ, Sinkala M, et al. Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus. Lancet. 2003;362(9398):1850-1853.
25. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351(3):217-228.
26. Dryden-Peterson S, Jayeoba O, Hughes MD, et al. Highly active anti-retroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana. J Acquir Immune Defc Syndr. 2011;58(3):353-357.
27. Donnell D, Baeten JM, Kiarie J, et al; Partners in Prevention HSV/ HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092-2098.
28. Zaidi J, Grapsa E, Tanser F, Newell ML, Barnighausen T. Dramatic increases in HIV prevalence after scale-up of antiretroviral treatment: a longitudinal population-based HIV surveillance study in rural kwazulu-natal. AIDS. Epub May 10, 2013.
29. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Available from http://www.who.int/hiv/pub/guidelines/ arv2013/download/en/. Accessed August 1, 2013.
30. Celum C, Hallett TB, Baeten JM. HIV-1 prevention with ART and PrEP: mathematical modeling insights into resistance, effectiveness, and public health impact. J Infect Dis. 2013;208(2): 189-191.
31. Granich R, Crowley S, Vitoria M, et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc. 2010;13:1.
32. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48-57.
33. Guidance on couples HIV testing and counselling - including antiretroviral therapy for treatment and prevention in serodiscordant couples. Geneva: World Health Organization; 2012.
34. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6): 493-505.
35. Osborne BJ, Sheth PM, Yi TJ, et al. Impact of antiretroviral therapy duration and intensifcation on isolated shedding of HIV-1 RNA in semen. J Infect Dis. 2013;207(8):1226-1234.
36. US Food and Drug Administration. [webpage on the Internet] Available from www.fda.gov. Accessed July 22, 2013.
37. Carter RJ, Dugan K, El-Sadr WM, et al. CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings. J Acquir Immune Defc Syndr. 2010;55(3):404-410.
38. Torpey K, Lartey M, Amenyah R, et al. Initiating antiretroviral treatment in a resource-constrained setting: does clinical staging effectively identify patients in need? Int J STD AIDS. 2009;20(6):395-398.
39. Emmett SD, Cunningham CK, Mmbaga BT, et al. Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. J Acquir Immune Defc Syndr. 2010;54(4):368-375.
40. Baveewo S, Ssali F, Karamagi C, et al. Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda. PLoS One. 2011;6(5):e19089.
41. Asboe D, Aitken C, Boffto M, et al; BHIVA Guidelines Subcommittee. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med. 2012;13(1):1-44.
42. Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72(9):e1-e25.
43. Ferreyra C, Yun O, Eisenberg N, et al. Evaluation of clinical and immu-nological markers for predicting virological failure in a HIV/AIDS treatment cohort in Busia, Kenya. PLoS One. 2012;7(11):e49834.
44. Arnedo M, Alonso E, Eisenberg N, et al. Monitoring HIV viral load in resource limited settings: still a matter of debate? PLoS One. 2012;7(12): e47391.
45. Ingole N, Mehta P, Pazare A, Paranjpe S, Sarkate P. Performance of immunological response in predicting virological failure. AIDS Res Hum Retroviruses. 2013;29(3):541-546.
46. Medina Lara A, Kigozi J, Amurwon J, et al; DART Trial Team. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One. 2012;7(4):e33672.
47. Stover J, Korenromp EL, Blakley M, et al. Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One. 2011;6(6):e21048.
48. Boyer S, March L, Kouanfack C, et al; Stratall ANRS 12110/ESTHER Study Group. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis. 2013;13(7):577-586.
49. Tayler-Smith K, Zachariah R, Massaquoi M, et al. Unacceptable attrition among WHO stages 1 and 2 patients in a hospital-based setting in rural Malawi: can we retain such patients within the general health system? Trans R Soc Trop Med Hyg. 2010;104(5):313-319.
50. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS. 2012;26(16):2059-2067.
51. Govindasamy D, van Schaik N, Kranzer K, Wood R, Mathews C, Bekker LG. Linkage to HIV care from a mobile testing unit in South Africa by different CD4 count strata. J Acquir Immune Defc Syndr. 2011;58(3):344-352.
52. Zachariah R, Reid SD, Chaillet P, Massaquoi M, Schouten EJ, Harries AD. Viewpoint: why do we need a point-of-care CD4 test for low-income countries? Trop Med Int Health. 2011;16(1):37-41.
53. Laursen L. Point-of-care tests poised to alter course of HIV treatment. Nat Med. 2012;18(8):1156.
54. Peeling RW, Holmes KK, Mabey D, Ronald A. Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect. 2006;82(5):v1-v6.
55. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-1826.
56. Spacek LA, Shihab HM, Lutwama F, et al. Evaluation of a low-cost method, the Guava EasyCD4 assay, to enumerate CD4-positive lymphocyte counts in HIV-infected patients in the United States and Uganda. J Acquir Immune Defc Syndr. 2006;41(5):607-610.
57. The CD4 Initiative [webpage on the Internet]. London: Imperial College London; 2006. Available from: http://www3.imperial.ac.uk/cd4. Accessed May 2, 2013.
58. Sukapirom K, Onlamoon N, Thepthai C, Polsrila K, Tassaneetrithep B, Pattanapanyasat K. Performance evaluation of the Alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings. J Acquir Immune Defc Syndr. 2011;58(2):141-147.
59. Jani IV, Sitoe NE, Chongo PL, et al. Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS. 2011;25(6):807-812.
60. + counting. IAS 2013; June 30-July 3, 2013; Kuala Lumpur, Malaysia. Available at http://pag.ias2013.org/Abstracts.aspx?AID=1471. Accessed August 1, 2013.
61. Estill J, Egger M, Blaser N, et al; IeDEA Southern Africa. Cost-effectiveness of point-of-care viral load monitoring of ART in resource-limited settings: mathematical modelling study. AIDS. Epub March 4, 2013.
62. Urdea M, Penny LA, Olmsted SS, et al. Requirements for high impact diagnostics in the developing world. Nature. 2006;444 Suppl 1: 73-79.
63. Lee HH, Dineva MA, Chua YL, Ritchie AV, Ushiro-Lumb I, Wisniewski CA. Simple amplifcation-based assay: a nucleic acid based point-of-care platform for HIV-1 testing. Journal Infect Dis. 2010;201: S65-S72.
64. Jani I, Meggi B, Vubil A, et al. Evaluation of point-of-care nucleic acid testing for HIV viral load and early infant diagnosis in primary health clinics: Mozambique. Abstract presented at Conference on Retroviruses and Opportunistic Infections; 2013; Atlanta, GA. March 3-6, 2013.
65. DART Trial Team, Mugyenyi P, Walker AS, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375(9709):123-131.
66. Bongomera G, Namata H, Nkhata M, et al. Lablite: baseline mapping survey of decentralised ART service provision in Malawi, Uganda and Zimbabwe. Conference abstract. 19th International AIDS Conference; July 22-July 27, 2012; Washington DC.
67. Grundy C, Medina Lara A, Winogron D, et al. Point-of-care CD4 tests can increase life-years saved with reduced costs compared to flow cyto-metric CD4 counting. Abstract presented at the Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2011; Rome.
68. Larson BA, Schnippel K, Ndibongo B, et al. Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa. J Acquir Immune Defc Syndr. 2012;61(2):e13-e17.
69. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011;378(9802):1572-1579.
70. Muchedzi A, Chadambuka A, Chikwinya B, Mahomva A. Evaluating the effect of the use of point-of-care CD4 machines on access to anti-retroviral therapy (ART) eligibility screening and ART initiation for HIV-positive pregnant women in Zimbabwe: towards elimination of new paediatric HIV infection by 2015. J Int AIDS Soc. 2012;15:282-282. Abstract presented at IAS; July 22-27; 2012; Washington, DC, USA.
71. Hatzold K, Gudukeya SB, Museta M, et al. Improved access to HAART through point of care CD4 cell count testing integration into HIV testing and counseling services in Zimbabwe. 6th IAS Conference on HIV Pathogenesis and Treatment; 2011; Rome. Conference Abstract; July 17- July 20, 2011.
72. Ciaranello AL, Myer L, Christensen S, et al. The cost-effectiveness of point-of-care CD4 testing in antenatal care in South Africa. Abstract presented at Conference on Retroviruses and Opportunistic Infections; 2013; Atlanta, GA. March 3-6, 2013.